Gender-associated expression of tumor markers and a small gene set in breast carcinoma.

Autor: Andres SA; Department of Biochemistry & Molecular Biology, J. Graham Brown Cancer Center and Institute for Molecular Diversity & Drug Design, University of Louisville, Louisville, KY 40202, USA., Smolenkova IA; Department of Biochemistry & Molecular Biology, J. Graham Brown Cancer Center and Institute for Molecular Diversity & Drug Design, University of Louisville, Louisville, KY 40202, USA., Wittliff JL; Department of Biochemistry & Molecular Biology, J. Graham Brown Cancer Center and Institute for Molecular Diversity & Drug Design, University of Louisville, Louisville, KY 40202, USA. Electronic address: jim.wittliff@louisville.edu.
Jazyk: angličtina
Zdroj: Breast (Edinburgh, Scotland) [Breast] 2014 Jun; Vol. 23 (3), pp. 226-33. Date of Electronic Publication: 2014 Mar 21.
DOI: 10.1016/j.breast.2014.02.007
Abstrakt: Breast carcinomas in both genders share pathological features, although differences in incidence, prognosis and survival are reported. Expression of 33 genes was investigated in male and female breast carcinomas in association with ER, PR, HER-2/neu and EGF-receptor. Among 98 male breast cancers, 82 were ER+ and 78 were PR+. ER and PR protein levels were greater in males compared to females, although no differences were observed in ESR1 and PGR expression. A difference was observed in binding affinities of PR but not ER between genders. No differences were observed in HER-2/neu, EGFR protein, or patient age. Expression of NAT1, TBC1D9, IL6ST, RABEP1, PLK1 and LRBA was elevated in carcinomas of males compared to those of females, in which ER status appeared to be related to expression. Over-expression of protein products of these genes represents novel molecular targets for development of gender-specific therapeutics and companion diagnostics.
(Copyright © 2014 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: